Sporadic inclusion body myositis: Diagnostic value of p62 immunostaining

Area of Science:

• Neurology
• Immunology
• Pathology

Background:

• Sporadic inclusion body myositis (sIBM) diagnosis is often delayed or confused with other disorders.
• Early diagnosis of sIBM and predicting progression from polymyositis (PM) to sIBM remain challenging.
• p62 immunostaining is proposed as a potential diagnostic aid for sIBM.

Observation:

• A case study of a 61-year-old patient diagnosed with polymyositis (PM) six years prior, who later presented with sporadic inclusion body myositis (sIBM).
• Muscle biopsies revealed a progression of p62 expression.
• Initial biopsy showed small, dotted p62 aggregates, while a later biopsy, coinciding with sIBM diagnosis, exhibited large p62 aggregates.

Findings:

• The study observed distinct p62 aggregate patterns in muscle fibers correlating with disease progression from PM to sIBM.
• Retrospective analysis of muscle biopsies demonstrated the evolution of p62 aggregates over a six-year period.
• The findings suggest p62 expression changes are indicative of sIBM development.

Implications:

• p62 immunostaining could potentially assist clinicians in differentiating PM patients who may develop sIBM.
• This biomarker may improve the accuracy and timeliness of sIBM diagnosis.
• Further systematic studies are needed to validate the utility of p62 in myositis diagnosis.